Statement on Recombinant DNA Research 
on Behalf of the 
Pharmaceutical Manufacturers Association 
Before the 
Senate Labor and Public Welfare Committee 
Sepibqer 2 !> 1975 
Mr. Chairman and Members of the Committee : 
I am C. Joseph StetleR/ President of the Pharmaceutical 
Manufacturers Assoc i at ion, an organization composed of 130 members 
THAT DISCOVER/ DEVELOP/ MANUFACTURE AND MARKET MOST OF THE PRESCRIPTION 
DRUGS AND A LARGE PERCENTAGE OF THE DIAGNOSTIC REAGENTS AND MEDICAL 
DEVICES AVAILABLE IN THE UNITED STATES. ACCOMPANYING ME ARE 
Dr. John G. Adam S/ PMA Vice President/ Scientific and Professional • 
Relations and Dr. Sidney UdenfrienD/ Vice President and Director of 
the Roche Institute of Molecular Biology, 
Our testimony hill be brief/ but we hope responsive to the 
Subcommittee's inquiry into the involvement of PMA member firms in 
recombinant DNA research and our views on the Guidelines recently 
PUBLISHED BY THE NATIONAL INSTITUTES Or HEALTH. 
The subject of todav's hearings is one which is recognized 
BY ALL ELEMENTS OF THE BIOMEDICAL RESEARCH COMMUNITY AS A MAJOR 
BREAKTHROUGH ALONG THE FRONTIERS OF SCIENCE. As AN INSTITUTION 
ENGAGED IN BIOMEDICAL RESEARCH/ THE DRUG INDUSTRY IS ACUTELY AWARE 
OF ITS SCIENTIFIC/ MORAL AND SOCIAL RESPONSIBILITIES IN THIS NEW FIELD 
[ 109 ] 
